OpenAI launches drug development AI model, challenging Google.

OpenAI is launching an early version of an artificial intelligence model aimed at accelerating drug discovery, joining tech companies in proving that AI can drive more scientific breakthroughs. The developer of ChatGPT announced on Thursday that the model, named GPT-Rosalind, is tailored for life science research, such as helping extract insights from massive amounts of data and translating research into patient-oriented medical applications. OpenAI said that the model will first be made available to select corporate clients in the form of research previews. The initial users include pharmaceutical companies Amgen, vaccine manufacturer Moderna, and the non-profit biological research organization Allen Institute. OpenAI, Anthropic, and Google under Alphabet are increasingly focusing on the application of AI in science and healthcare, including assisting in new drug development and analyzing personal medical data.